Krystal Biotech, Inc. Q3 2025 Earnings Recap

KRYS Q3 2025 November 5, 2025

Get alerts when KRYS reports next quarter

Krystal Biotech delivered a strong Q3 2025, with VYJUVEK revenues reaching $97.8 million, bolstered by recent expansions in Europe and Japan. The company is well-positioned for sustained growth with an expanding prescriber base and new clinical programs underway.

Earnings Per Share Beat

$2.66 vs $1.12 est.

+137.5% surprise

Revenue Miss

97800000 vs 105299500 est.

-7.1% surprise

Market Reaction

1-Day -1.66%

5-Day -1.84%

30-Day +7.25%

See KRYS alongside your other holdings

Add to your portfolio — free

Key Takeaways

VYJUVEK revenues total $97.8 million for Q3, contributing to over $623 million since the product’s launch.
Gross margins remained robust at 96%, with an acceleration in over 40 new reimbursement approvals in the U.S. since the last earnings call.
Successful launches of VYJUVEK in Germany, France, and Japan are set to enhance patient access and treatment availability.
The updated U.S. label for VYJUVEK now includes patients from birth, optimizing the product's market position and potential for higher compliance.
Initiation of a new clinical program for Hailey-Hailey disease reinforces Krystal’s commitment to rare disease treatments and expands their innovative pipeline.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit KRYS on AllInvestView.